Gene therapy for kidney disease

Bibliography

• JAPAN SOCIETY FOR DIALYSIS THERAPY: An overview of regular dialysis treatment in Japan as of December 31, 1998). (1999).
   Google Scholar
• UNITED STATES RENAL DATA SYSTEM: USRDS 1998 Annual Data Report. Natl. Inst. Health, Bethesda, USA (1998).
   Google Scholar
• TOMITA N, HIGAKI J, MORISHITA R et al: Direct in vivo gene introduction into rat kidney. Biochem. Biophys. Res. Commun. (1992) 186:129–134.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, FUJIWARA Y, UEDA N, KANEDA Y, KAMADA T, IMAI E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. (1993) 92:2597–2601.
   PubMed Web of Science ®Google Scholar
• •This is the first demonstration of growth factor gene transfer into the glomeruli. The selective expression of the growth factors caused morphological change in the kidney.
   Google Scholar
• HEIKKILA P, PARPALA T, LUKKARINEN O, WEBER M, TRYGGVASON K: Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system-first steps towards gene therapy of Alport syndrome. Gene Ther. (1996) 3:21–27.
   PubMed Web of Science ®Google Scholar
• •Intense and diffuse expression of the transgene occurred after using an adenovirus vector with a perfusion system. The gene transfer expression mainly occurred in podocyte of the glomerulus.
   Google Scholar
• OBERBAUER R, SCHREINER G, MEYER T: Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int. (1995) 48:1226–1232.
   PubMed Web of Science ®Google Scholar
• RAPPAPORT J, HANSS B, KOPP J et al: Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. (1995) 47:1462–1469.
   PubMed Web of Science ®Google Scholar
• LIEN Y, LW L: Liposome-mediated gene transfer intokidney tubules. Exp. Nephrol. (1997) 5:132–136.
   PubMedGoogle Scholar
• MOULLIER P, FRIEDLANDER G, CALISE D, RONCO P,PERRICAUDET M, FERRY N: Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int. (1994) 45:1220–1225.
   PubMed Web of Science ®Google Scholar
• BOSCH R, WOOLF A, FINE L: Gene transfer into themammalian kidney: Direct retrovirus transduction of regenerating tubular epithelial cells. Exp. Nephrol. (1993) 1:49–54.
   PubMedGoogle Scholar
• LIPKOWITZ M, HANSS B, TULCHIN N et al: Transductionof renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors. J. Am. Soc. Nephrol. (1999) 10:1908–1915.
   PubMed Web of Science ®Google Scholar
• LAI L, CHAN D, ERICKSON R, HSU S, LIEN Y: Correction ofrenal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy. J. Clin. Invest. (1999) 101:1320–1325.
   Web of Science ®Google Scholar
• •This is the first report of gene therapy for inherited mouse renal tubular acidosis, by supplementation of carbonic anhydrase II gene, targeting proximal tubular cells by cationic liposome. The acidosis was corrected for three weeks by a single injection of plasmid-liposome complex.
   Google Scholar
• ZHU G, NICOLSON A, COWLEY B, ROSEN S, SUKHATME V: In vivo adenovirus-mediated gene transfer into normal and cystic rat kidneys. Gene Ther. (1996) 3:298–304.
   PubMed Web of Science ®Google Scholar
• •Successful gene transfer to the vasculature in the medulla of a chilled kidney using an adenovirus vector and vasodilator.
   Google Scholar
• TSUJIE M, ISAKA Y, ANDO Y et al.: Gene transfer targeting interstitial fibroblasts by the artificial viral envelope type haemagglutinating virus of Japan liposome method. Kidney Int. (2000).
   Google Scholar
• •The first demonstration of the in vivo gene transfer to the interstitial fibroblast.
   Google Scholar
• KITAMURA M, TAYLOR S, UNWIN R, BURTON S, SHIMIZU F, FINE LG: Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification and sustained expression of an exogenous gene in vivo. J. Clin. Invest. (1994) 94:497–505.
   PubMed Web of Science ®Google Scholar
• KITAMURA M, SUTO T: Transfer of genetically engineered macrophages into the glomerulus. Kidney Int. (1997) 51:1274–1279.
   PubMed Web of Science ®Google Scholar
• YOKOO T, UTSUNOMIYA Y, OHASHI T et al.: Inflamedsite-specific gene delivery using bone marrow-derived CD11b+CD18+vehicle cells in mice. Hum. Gene Ther. (1998) 9:1731–1738.
   PubMed Web of Science ®Google Scholar
• NAITO T, YOKOYAMA H, MOORE K, DRNOFF G, MULLIGAN C, KELLY V: Macrophage growth factors introduced into the kidney initiate renal injury. Mol. Med. (1996) 2:297–312.
   PubMed Web of Science ®Google Scholar
• ZEIGLER S, KERBY J, CURIEL D, DIETHELM A, THOMPSONJ: Molecular conjugate-mediated gene transfer into isolated human kidneys. Transplantation (1996) 61:812–817.
   PubMed Web of Science ®Google Scholar
• MARCEL T, GRAUSZ J: The TMC worldwide gene therapyenrollment report, end 1996. Hum. Gene Ther. (1997) 8:775–800.
   PubMed Web of Science ®Google Scholar
• YANG Y, LI Q, ERTL H, WILSON J: Cellular and humoralimmune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. j Virol. (1995) 69:2004–2015.
   PubMed Web of Science ®Google Scholar
• DEMATTEO R, CHU G, AHN M, CHANG E, BARKER C, MARKMANN J: Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosup-pression. j Virol. (1997) 71:5330–5335.
   PubMed Web of Science ®Google Scholar
• SUROSKY R, URABE M, GODWIN S etal. Adeno-associate virus rep proteins target DNA sequences to a unique locus in the human genome. J. Virol. (1997) 71:7951–7959.
   Google Scholar
• RIVADENEIRA E, POPESCU N, ZIMONJIC D et al.:Recombinant adeno-associated virus integrates at diverse sites in the human genome. Int. J. Oncol. (1999) 12:805–810.
   Web of Science ®Google Scholar
• BAUDARD M, FLOTTE T, ARAN J et al.: Expression of thehuman multidrug resistance and glucocerebrosidase cDNA from adeno-associated vectors: Efficient promotor activity of AAV sequences and in vivo delivery via liposomes. Hum. Gene Ther. (1996) 7:1309–1322.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, AKAGI Y, KANEDA Y, IMAI E: TheHVJ-liposome method. Exp. Nephrol. (1998) 6:144–147.
   PubMedGoogle Scholar
• ARAI M, WADA A, ISAKA Y et al: In vivo transfection ofgenes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem. Biophys. Res. Commun. (1995) 206:525–532.
   PubMed Web of Science ®Google Scholar
• SAEKI Y, MATSUMOTO N, NAKANO Y, MORI M, AWAI K,KANEDA Y: Development and characterization of cationic liposomes conjugated with HVJ (Sendai Virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. (1997) 8:2133–2141.
   PubMed Web of Science ®Google Scholar
• SAEKI Y, WATAYA-KANEDA M, TANAKA K, KANEDA Y:Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposome. Gene Ther. (1998) 5:1031–1037.
   PubMed Web of Science ®Google Scholar
• WISOKENSKI D, YATES L: Multiple EBNA-1 binding sitesare required to form an EBNA-1-dependent enhancer and to activate a minimal replication origin within oriP of Epstein-Barr virus. J. Virol. (1989) 63:2657–2666.
   PubMed Web of Science ®Google Scholar
• TSUJIE M, ISAKA Y, NAKAMURA H, KANEDA Y, IMAI E,HORI M: Prolonged transgene expression in glomeruli using an Epstein-Barr virus replicon vector system combined with AVE type HVJ liposome. Kidney Int. In submission.
   Google Scholar
• KITAMURA M: Gene delivery into the glomerulus via mesangial cell vectors. Exp. Nephrol (1997) 5:118–125.
   PubMedGoogle Scholar
• KELLY V, MOORE K: Application of a gene transfer strategy to identify molecules that incite autoimmune kidney injury. Exp. Nephrol. (1997) 5:144–151.
   PubMedGoogle Scholar
• STEIN C, CHENG Y: Antisense oligonucleotides as therapeutic agents Is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• WANGER R: Gene inhibition using antisense oligode-oxynucleotides. Nature (1994) 372:333–335.
   PubMed Web of Science ®Google Scholar
• ASKARI FM: Antisense-oligonucleotide therapy. N Engl. J. Med. (1996) 334:316–318.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, AGRAWAL S: In vivo studies with antisenseoligonucleotides. TIPS (1997) 18:12–19.
   PubMed Web of Science ®Google Scholar
• AKAGI Y, ISAKA Y, ARAI M et al.: Inhibition of TGF-01expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1996) 50:148–155.
   PubMed Web of Science ®Google Scholar
• •The first report to show the use of antisense therapy for experimental glomerulonephritis. HVJ-liposome mediated antisense delivery via the renal artery produced gene transfer to the glomerular mesangial cells.
   Google Scholar
• MORISHITA R, GIBBONS G, HORIUCHI M et al.: A genetherapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle prolifera-tion in vivo. Proc. Natl. Acad. Sci. USA (1995) 92:5855–5859.
   PubMed Web of Science ®Google Scholar
• MAESHIMA Y, KASHIHARA N, YASUDA T et al.: Inhibitionof mesangial cell proliferation by E2F decoy oligonu-cleotide in vitro and in vivo. J. Clin. Invest. (1998) 101:2589.
   PubMed Web of Science ®Google Scholar
• •This is the first report that utilised a decoy to prevent the development of experimental glomerulonephritis. E2F decoys were successfully transduced to glomerular mesangial cells by the liposome method.
   Google Scholar
• TOMITA N, MORISHITA R, HASHIZUME M et al.:Feasibility of decoy strategy by targeting the transcrip-tion factor NF-KB in anti-GBM glomerulonephritis. J. Am. Soc. Nephrol. (1997) 8:467A.
   Web of Science ®Google Scholar
• YOKOO T, OHASHI T, UTSNOMIYA Y et al.: Prophylaxisof antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells. Hum. Gene Ther. (1999) 10:2673–2678.
   PubMed Web of Science ®Google Scholar
• •This report showed the potential of modified macrophages to treat the glomerulonephritius. The macrophages infiltrated the inflamed glomeruli and secreted IL-lra locally.
   Google Scholar
• NOIRI E, PERESLENI T, MILLER F, GOLIGORSKY MS: In vivo targeting of inducible NO synthase with oligode-oxynucleotides protects rat kidney against ischemia. Clin. Invest. (1996) 97:2377–2383.
   Google Scholar
• •The first report to show the use of antisense therapy for acute renal failure. Intravenous injection of antisense oligonucleotides accumulated in the proximal tubule.
   Google Scholar
• OBERBAUER R, SCHREINER GF, BIBER J, MURER H, MEYER TW: In vivo suppression of the renal Na+/Pi cotransporter by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA (1996) 93:4903–4906.
   PubMed Web of Science ®Google Scholar
• RISDON R, SLOPER J, DE VARDENER H: Relationshipbetween renal function and histologic changes found in renal-biopsy specimens from patients with persis-tent glomerulonephritis. Lancet (1968) 2:363–366.
   PubMed Web of Science ®Google Scholar
• SCHAINUCK LI, STRIKER GE, CUTLER RE, BENDITT EP:Structural-functional correlations in renal disease. II. The correlations. Hum. Pathol. (1970) 1:631–641.
   PubMedGoogle Scholar
• EDDY AA: Molecular insights into renal interstitialfibrosis [editorial]. J. Am. Soc. Nephrol. (1996) 7:2495–2508.
   PubMed Web of Science ®Google Scholar
• BORDER W, NABLE N: Transforming growth factor intissue fibrosis. N Engl. J. Med. (1994) 331:1286–1292.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, TSUJIE M, ANDO Y et al.: Introduction oftransforming growth factor-B1 antisense oligode-oxynucleotides into renal interstitial fibroblasts blocks interstitial fibrosis in unilateral ureteral obstruction. Kidney Int. (In submission).
   Google Scholar
• WOOLF A, PALMER S, SNOW M, FINE L: Creation of afunctioning chimeric mammalian kidney. Kidney Int. (1990) 38:991–997.
   PubMed Web of Science ®Google Scholar
• TRIPATHY S, SVENSSON E, BLACK H et al: Long-term-expression of erythropoietin in the systemic circula-tion of mice after intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad. Sci. USA (1996) 93:10876–10880.
   PubMed Web of Science ®Google Scholar
• TSURUMI Y, TAKESHITA S, CHEN D et al.: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collat-eral development and tissue perfusion. Circulation (1996) 94:3281–3290.
   PubMed Web of Science ®Google Scholar
• BLEZINGER P, WANG J, GONDO Metal.: Systemic inhibi-tion of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotechnol. (1999) 17:343–348.
   Google Scholar
• TOKUI M, TAKEI I, TASHIRO F et al.: Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5. Biochem. Biophys. Res. Comm. (1997) 233:527–531.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, BREES DK, IKEGAYA K et al.: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. (1996) 2:418–423.
   PubMed Web of Science ®Google Scholar
• ••This is the first report to demonstrate gene therapy forexperimental glomerulosclerosis. Systemic decorin gene transfer to the muscle provided anti-TGF-6 action in glomeruli.
   Google Scholar
• ISAKA Y, AKAGI Y, ANDO Y et al.: Gene therapy by transforming growth factor-b receptor-IgG Fcchimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1999) 55:465–475.
   PubMed Web of Science ®Google Scholar
• •The transfer of soluble TGF-6 receptors into skeletal muscle was achieved, suppressing TGF-6 action in the experimental glomerulonephriti and the accumulation of ECM.
   Google Scholar
• KESSLER P, PODSAKOFF G, CHEN X et al.: Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Nati Acad. Sci. USA (1996) 93:14082–14087.
   PubMed Web of Science ®Google Scholar
• MARSHALL E: Gene therapy death prompts review of adenovirus vector. Science (1999) 286:2244–2245.
   PubMed Web of Science ®Google Scholar
• BESTOR T: Gene silencing as a threat to the success of gene therapy. J. Clin. Invest. (2000) 105:409–411.
   PubMed Web of Science ®Google Scholar
• SWENSON K, KE B, WANG T et al: Fas ligand gene transfer to renal allografts in rats. Transplantation (1998) 65:155–160.
   PubMed Web of Science ®Google Scholar
• •This report showed the potential of gene therapy for transplant kidneys.
   Google Scholar
• AZUMA H, TAKAHARA S, KITAMURA M et al.: Effect of hepatocyte growth factor on chronic rejection in rat renal allografts. Transplant Proc. (1999) 31:854–855.
   PubMed Web of Science ®Google Scholar